Abstract
Starting from non-peptidic sst(1)-selective somatostatin receptor antagonists, first compounds with mixed sst(1)/sst(3) affinity were identified by directed structural modifications. Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst(3)-subtype selective somatostatin antagonists based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety. These compounds can efficiently be synthesized and show promising PK properties in rodents.
Copyright 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Crystallography, X-Ray
-
Humans
-
Isoquinolines / chemical synthesis*
-
Isoquinolines / chemistry*
-
Isoquinolines / pharmacokinetics
-
Molecular Conformation
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / genetics
-
Protein Isoforms / metabolism
-
Rats
-
Receptors, Somatostatin / antagonists & inhibitors*
-
Receptors, Somatostatin / genetics
-
Receptors, Somatostatin / metabolism
-
Recombinant Proteins / antagonists & inhibitors
-
Recombinant Proteins / genetics
-
Recombinant Proteins / metabolism
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
(4-(3,4-difluorophenyl)-piperazine-1-yl)-(2-(3-(6-methoxypyridin- 3-yl)-2-methylpropyl)decahydroisoquinoline-4-yl)methanone
-
Isoquinolines
-
Protein Isoforms
-
Receptors, Somatostatin
-
Recombinant Proteins
-
isoquinoline